Liminatus Pharma (LIMN) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($5.0 million vs $3.4 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | SLXN |
|---|---|---|
| Share price | $3.69 | $0.2349 |
| Market cap | $4.96M | $3.40M |
| 1-day change | -4.65% | -7.37% |
| EPS (TTM) | $-23.50 | $-27.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $40.70 |
| 52-week low | $3.29 | $0.222 |
| Distance from 52-week high | -97.39% | -99.42% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2028.57% |
| Average volume | 453.28K | 9.90M |
| Shares outstanding | 1.34M | 14.47M |
| Employees | 1 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
LIMN vs SLXN FAQ
Which is bigger, Liminatus Pharma or Silexion Therapeutics?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $4.96M compared with $3.40M for Silexion Therapeutics (SLXN).
Are Liminatus Pharma and Silexion Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.